Sang Kyu Park1, Sang Hyun Suh2, Kyeong Sool Jang3, Dong Kyu Jang3, Dong Young Jo4, Yong Sam Shin5. 1. Department of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 2. Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. suhsh11@yuhs.ac. 3. Department of Neurosurgery, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea. 4. Department of Neurosurgery, Seoul Ewha Womans University Medical Center, Seoul, Republic of Korea. 5. Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: Severe intracranial atherosclerotic stenosis (ICAS) is a major cause of stroke. Although percutaneous transluminal angioplasty and stenting (PTAS) treatment methods have increased over the last decade as alternative therapies, there is debate regarding the best method of treatment, with medical and surgical therapies often suggested. METHODS: We analyzed the long-term follow-up results from 5 years of intracranial stenting for intracranial stenosis from three stroke centers. The primary endpoints were early stroke complications or death within 30 days after stent insertion, and the secondary endpoint was a recurrent stroke between 30 days and 60 months. Correlating factors and Kaplan-Meier survival curves for recurrent stroke and in-stent restenosis (ISR) were also obtained. RESULTS: Seventy-three PTAS in 71 patients were examined in this study. The primary and secondary endpoints were all 8.2% (n = 6), and restenosis was 13.7% (n = 10) during the 5-year follow-up. The primary endpoints were significantly frequent in the high National Institutes of Health Stroke Scale (NIHSS) and early stent (≤ 7 days after dual antiplatelet medication) groups. Secondary endpoint and ISR were identically frequent in the younger age group and in the presence of tandem stenosis in other major intracranial arteries. The cumulative probability of recurrent stroke and ISR at 60 months was 16.4% and 14.1%, respectively. CONCLUSIONS: This study shows that PTAS is safe and effective for major ICAS. Reducing the early complication rate is still an important factor, despite the fact that long-term stroke recurrence was low.
BACKGROUND: Severe intracranial atherosclerotic stenosis (ICAS) is a major cause of stroke. Although percutaneous transluminal angioplasty and stenting (PTAS) treatment methods have increased over the last decade as alternative therapies, there is debate regarding the best method of treatment, with medical and surgical therapies often suggested. METHODS: We analyzed the long-term follow-up results from 5 years of intracranial stenting for intracranial stenosis from three stroke centers. The primary endpoints were early stroke complications or death within 30 days after stent insertion, and the secondary endpoint was a recurrent stroke between 30 days and 60 months. Correlating factors and Kaplan-Meier survival curves for recurrent stroke and in-stent restenosis (ISR) were also obtained. RESULTS: Seventy-three PTAS in 71 patients were examined in this study. The primary and secondary endpoints were all 8.2% (n = 6), and restenosis was 13.7% (n = 10) during the 5-year follow-up. The primary endpoints were significantly frequent in the high National Institutes of Health Stroke Scale (NIHSS) and early stent (≤ 7 days after dual antiplatelet medication) groups. Secondary endpoint and ISR were identically frequent in the younger age group and in the presence of tandem stenosis in other major intracranial arteries. The cumulative probability of recurrent stroke and ISR at 60 months was 16.4% and 14.1%, respectively. CONCLUSIONS: This study shows that PTAS is safe and effective for major ICAS. Reducing the early complication rate is still an important factor, despite the fact that long-term stroke recurrence was low.
Authors: Scott E Kasner; Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano; Harry J Cloft Journal: Circulation Date: 2006-01-23 Impact factor: 29.690
Authors: Annette Compter; H Bart van der Worp; Wouter J Schonewille; Jan Albert Vos; Jelis Boiten; Paul J Nederkoorn; Maarten Uyttenboogaart; Rob T Lo; Ale Algra; L Jaap Kappelle Journal: Lancet Neurol Date: 2015-04-20 Impact factor: 44.182
Authors: Michael J Alexander; Alois Zauner; John C Chaloupka; Blaise Baxter; Richard C Callison; Rishi Gupta; Shlee S Song; Wengui Yu Journal: Stroke Date: 2019-04 Impact factor: 7.914
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: David Fiorella; Elad I Levy; Aquilla S Turk; Felipe C Albuquerque; David B Niemann; Beverly Aagaard-Kienitz; Ricardo A Hanel; Henry Woo; Peter A Rasmussen; L Nelson Hopkins; Thomas J Masaryk; Cameron G McDougall Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: N Engl J Med Date: 2011-09-07 Impact factor: 91.245
Authors: Arani Bose; Marius Hartmann; Hans Henkes; Hon Man Liu; Michael M H Teng; Istvan Szikora; Ansgar Berlis; Jurgen Reul; Simon C H Yu; Michael Forsting; Matt Lui; Winston Lim; Siu Po Sit Journal: Stroke Date: 2007-03-29 Impact factor: 7.914
Authors: Colin P Derdeyn; Marc I Chimowitz; Michael J Lynn; David Fiorella; Tanya N Turan; L Scott Janis; Jean Montgomery; Azhar Nizam; Bethany F Lane; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; John R Lynch; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: Lancet Date: 2013-10-26 Impact factor: 79.321
Authors: Hugh S Markus; Susanna C Larsson; Wilhelm Kuker; Ursula G Schulz; Ian Ford; Peter M Rothwell; Andrew Clifton Journal: Neurology Date: 2017-08-23 Impact factor: 9.910